COINTURK FINANCECOINTURK FINANCECOINTURK FINANCE
  • Investing
  • Technology News
  • Business
  • Fintech
  • Startup
  • About Us
  • Contact
Search
Health
  • About Us
  • Contact
Entertainment
  • Investing
  • Business
  • Fintech
  • Startup
© 2024 BLOCKCHAIN IT. >> COINTURK FINANCE
Powered by LK SOFTWARE
Reading: Mabylon Secures Funding to Advance Antibody Therapeutics
Share
Font ResizerAa
COINTURK FINANCECOINTURK FINANCE
Font ResizerAa
Search
  • Investing
  • Technology News
  • Business
  • Fintech
  • Startup
  • About Us
  • Contact
Follow US
© 2025 BLOCKCHAIN Information Technologies. >> COINTURK FINANCE
Powered by LK SOFTWARE
Track all markets on TradingView
COINTURK FINANCE > Business > Mabylon Secures Funding to Advance Antibody Therapeutics
Business

Mabylon Secures Funding to Advance Antibody Therapeutics

Overview

  • Mabylon AG raised CHF 30M for antibody therapeutics focusing on allergies.

  • Funds will advance MY006, MY010, and MY011 allergy treatment programs.

  • Dr. Thomas Hecht joins Mabylon's board, replacing Prof. Adriano Aguzzi.

COINTURK FINANCE
COINTURK FINANCE 2 months ago
SHARE

Zurich-based biotech company Mabylon AG has successfully secured CHF 30 million, equivalent to around €32 million, from existing private investors. This funding consists of equity investment and convertible loans, with significant contributions from former Roche management and board members. Through this financial boost, Mabylon aims to push forward its research in antibody therapeutics, with promising potential in the fields of allergy, inflammation, and neurology. By leveraging this backing, the biotech firm seeks to bring innovative and effective solutions to these pressing health concerns.

Contents
What is Mabylon’s Main Objective?What Are the Leadership Changes at Mabylon?

The recent funding initiative aligns with Mabylon’s history of innovative strides in medicine. In earlier phases, the company has set ambitious goals to revolutionize allergy and neurology treatments through human-derived antibodies. Mabylon’s previous achievements laid a foundation that enabled the company to attract attention from prominent investors and stakeholders, particularly those affiliated with established industry giant Roche. This funding solidifies Mabylon’s trajectory towards achieving its research objectives.

What is Mabylon’s Main Objective?

The newly acquired funds will primarily support Mabylon’s lead program, MY006, which focuses on creating a tri-specific antibody designed to neutralize peanut allergens. The company plans to bring MY006 through to the completion of a Phase Ia/b clinical trial by 2027. Additionally, Mabylon is working on MY010 and MY011, each targeting various allergens such as the birch Bet v 1 allergen and grass pollen allergies. By expanding its research and discovery programs, the biotech company commits to addressing diversified allergenic challenges.

What Are the Leadership Changes at Mabylon?

Mabylon also announced the election of Dr. Thomas Hecht as a new board member, replacing Prof. Adriano Aguzzi, whose term concluded in June 2025. Dr. Hecht’s extensive industry experience is expected to facilitate the growth and commercial success of Mabylon’s allergen-neutralizing solutions. This change in leadership is perceived as a strategic move to usher in a fresh perspective and added expertise to the company. Additionally, Dr. Hecht’s guidance is anticipated to be instrumental in navigating the complex biotechnology landscape.

CEO Alcide Barberis underscored the importance of the funding during a trying global economic period and expressed optimism regarding the company’s strategic direction, stating,

“We are very pleased to have closed a CHF 30 million financing agreement in such a challenging global funding environment.”

His remarks reflect the company’s resilience and adaptability to market conditions, ensuring that research initiatives remain unaffected by broader financial challenges.

Chairman Gottlieb Keller shared insights into how the funds will fuel Mabylon’s innovation pipeline:

“MY006 is a multi-specific anti-allergen antibody for the prophylactic treatment of peanut allergy, an indication with a high unmet medical need.”

His statement highlights the company’s commitment to addressing pressing health needs through state-of-the-art biotechnology developments.

Mabylon’s focus remains on utilizing human-derived antibodies, which offer greater efficacy compared to those sourced from traditional methods like animal models. This approach has the potential to produce more effective treatments by targeting critical elements of allergens, thus significantly advancing the understanding of allergy mechanisms and pathogenesis.

Mabylon’s future seems promising with the secured funding and strategic leadership changes. By concentrating on high-priority areas of allergy therapies and leveraging human-derived antibody technology, the company is well-placed to address unmet medical needs. Potential breakthroughs in this research could lead to new standards in preventative allergy treatments if successful clinical trials result in viable therapeutic applications.

You can follow our news on Telegram and Twitter (X)
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.

You Might Also Like

Optics11 Life Secures Funding to Expand Mechanobiology Tools

Gen AI Rapidly Alters Technology Adoption Landscape

Mastercard Expands Personalized Advertising with New Digital Media Network

Investors Flood Nscale with $433M Pre-Series C Funding

Fifth Third Bank and OrthoAlliance Address Healthcare’s Revenue Challenges

Share This Article
Facebook Twitter Copy Link Print
Previous Article CoreVitals Expands Personalised Health Care Options in the UK
Next Article Retirees Weigh Portfolio Strategies with Market Volatility Looming
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

AI Infrastructure Startup Nscale Secures $433 Million in Rapid Funding Boost
COINTURK FINANCE COINTURK FINANCE 1 hour ago
Dott Expands E-bike Fleet in Paris with New Segway Model
COINTURK FINANCE COINTURK FINANCE 2 hours ago
SeaBeLife Gains €2 Million to Propel Drug Development
COINTURK FINANCE COINTURK FINANCE 3 hours ago
SMBs Demand Accelerated Payments As Banks Favor Large Enterprises
COINTURK FINANCE COINTURK FINANCE 4 hours ago
Spotify Shifts Leadership as Daniel Ek Takes on New Role
COINTURK FINANCE COINTURK FINANCE 4 hours ago
//

COINTURK was launched in March 2014 by a group of tech enthusiasts focused on the internet and new technologies.

CATEGORIES

  • Investing
  • Business
  • Fintech
  • Startup

OUR PARTNERS

  • COINTURK NEWS
  • BH NEWS
  • NEWSLINKER

OUR COMPANY

  • About Us
  • Contact
COINTURK FINANCECOINTURK FINANCE
Follow US
© 2025 BLOCKCHAIN Information Technologies. >> COINTURK FINANCE
Powered by LK SOFTWARE
Welcome Back!

Sign in to your account

Lost your password?